Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when REGN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRegeneron pre-announces $127M R&D charge, cutting Q2 EPS by ~$1.00
Filed July 6, 2026 · Period ending July 6, 2026 · ~1 min read
Key Changes
-
high
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
-
medium
The company defines acquired IPR&D charges to include asset acquisitions, up-front payments, opt-in payments, development milestones, and equity premiums tied to collaboration deals; does not forecast these due to uncertain timing and magnitude.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
low
Q2 2026 results are preliminary and unaudited, subject to final closing procedures; actual results may differ from disclosed estimates.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
Summary
Regeneron pre-announced a $127 million pre-tax charge for acquired in-process research and development in its second quarter 2026, stemming from up-front and opt-in payments under collaboration and licensing agreements. The charge will reduce both GAAP and non-GAAP earnings per diluted share by approximately $1.00.
The company does not forecast such charges because their timing and size are inherently uncertain, making this a mid-quarter disclosure rather than part of regular guidance. For retail holders, the immediate impact is a one-time EPS hit in Q2 results. The charge reflects deal-making activity—payments to advance pipeline programs through partnerships—rather than operational underperformance.
Regeneron's business development strategy routinely involves such transactions, and the company has chosen to disclose this particular charge ahead of earnings due to its magnitude. The figures are preliminary and subject to final closing procedures, so actual results may vary when Q2 earnings are reported.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the second quarter 2026 will include an acquired in-process research and development (“IPR&D”) charge of approximately $127 million on a pre-tax basis. This charge relates to up-front and opt-in payments in connection with collaboration and licensing agreements. The acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for the second quarter 2026 by approximately $1.00.
Regeneron pre-announces a $127 million pre-tax charge for acquired in-process research and development in Q2 2026, stemming from up-front and opt-in payments under collaboration and licensing agreements. This charge will reduce both GAAP and non-GAAP earnings per diluted share by approximately $1.00. The company notes these charges are not forecasted due to the uncertain timing and magnitude of such transactions.
Added in current filing · verify on EDGAR →
Acquired IPR&D charges may include IPR&D acquired in connection with asset acquisitions as well as up-front, opt-in, certain development milestone payments, and premiums paid on equity securities related to collaboration and licensing agreements. Regeneron does not forecast such acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period.
The filing clarifies that acquired IPR&D charges encompass not only asset acquisitions but also up-front payments, opt-in payments, certain development milestones, and premiums on equity securities tied to collaboration and licensing deals. Regeneron explicitly states it does not forecast these charges because their occurrence, size, and timing are uncertain, explaining why this disclosure is a pre-announcement rather than part of regular guidance.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Regeneron’s results for the second quarter 2026 have not been finalized and are subject to Regeneron’s financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary (unaudited) estimates described herein.
The company cautions that Q2 2026 results are preliminary and unaudited, subject to final closing procedures. Actual results may differ from the $127 million charge and $1.00 per share impact disclosed here. This is standard language for pre-announcement filings but reminds investors the figures are estimates.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 10, 2026 · How we verify